Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.
Bio-Rad Diabetes Division

Blood Glucose Test Recommended for All Hospitalized Patients

By Labmedica International staff writers
Posted on 23 Jan 2012
It is recommended that all patients should have their blood glucose levels tested on admission to a hospital, irrespective of whether they have been diagnosed with diabetes or not.

Professional endocrinologists has released new clinical practice guidelines recommendations for practical and safe glycemic targets as well as offering protocols and system improvements needed to achieve glycemic goals for hospitalized patients in a noncritical care setting.

A team of experts, led by those at Emory University School of Medicine (Atlanta, GA, USA) have published a new guideline which contains consensus recommendations from experts in the field for the management of diabetes in hospitalized patients. Hyperglycemia, or high blood sugar (glucose) levels, is a common, serious and expensive healthcare problem in hospitalized patients that is linked to an increased risk of complications and mortality. It can also affect nondiabetic hospitalized patients. According to observational studies, 32% to 38% of patients in community hospitals suffer from hyperglycemia. Improving glycemic control leads to lower hospital complications in general medicine and surgery patients.

The recommendations include that most hospitalized patients with noncritical illness glycemic targets should have a premeal glucose target of less than 140 mg/dL and random blood glucose of less than 180 mg/dL. Also that all inpatients with known diabetes or with hyperglycemia of greater than 7.8 mmol/liter (140 mg/dL) be assessed with a hemoglobin A1C (HbA1C) level if this has not been performed in the preceding 2-3 months. Additional recommendations include a premeal glucose target of less than 140 mg/dL (7.8 mmol/liter) and a random blood glucose of less than 180 mg/dL (10.0 mmol/L) for the majority of hospitalized patients with noncritical illness. They recommend implementation of a standardized hospital-wide, nurse-initiated hypoglycemia treatment protocol to prompt immediate therapy of any recognized hypoglycemia, defined as blood glucose below 3.9 mmol/L (70 mg/dL).

The Clinical Practice Guideline (CPG) Program was established by The Endocrine Society (Chevy Chase, MD, USA). It provides endocrinologists and other clinicians with evidence-based recommendations for diagnosing and treating endocrine-related conditions. A consortium of topic-related endocrine experts creates each CPG recommendation based on scientific reviews of literature. The recommendations were published in the January 2012 issue of the Journal of Clinical Endocrinology & Metabolism (JCEM).

Related Links:
Emory University School of Medicine
The Endocrine Society



KARL HECHT GMBH & CO KG
DIASYS DIAGNOSTIC SYSTEMS
77 ELEKTRONIKA

Channels

Hematology

view channel

Magnetic Resonance Improves Approach to Measuring Hemostasis Parameters

Two studies evaluating a magnetic resonance based detector for hemostasis measurements found its multiplex results to be rapid and accurate using lower blood volumes. At the International Society on Thrombosis and Hemostasis (ISTH) 2015 Congress (Toronto, Canada), T2 Biosystems, Inc. (Lexington, MA, USA) presented results... Read more

Lab Tech.

view channel
Image: Verigene System instrumentation consists of a Verigene Reader and one or multiple Verigene Processor SPs (Photo courtesy of Nanosphere).

Directed Molecular Diagnostic Tests Highlight Recent Microbiology Conference

The performance of a series of directed molecular diagnostic tests was confirmed by several studies presented at a recent microbiology conference. Nanosphere (Northbrook, IL, USA) manufactures tests... Read more

Industry News

view channel

QIAGEN Expands Diagnostics Menu in Partnership with Seegene

In a new collaboration, Seegene Inc. (Soul, Republic of Korea) will use its proprietary next-generation qPCR technology in developing new multiplex assays for the flagship platform of Qiagen NV (Venlo, Netherlands and Hilden, Germany). Seegene will develop a menu of multiplex assay panels for the modular QIAsymphony... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.